Figure 1
Figure 1. Kaplan-Meier analyses of response. PFS for all patients (A) and DR (B) for all responders (PR and CR) treated with fludarabine, cyclophosphamide, rituximab, and lumiliximab.

Kaplan-Meier analyses of response. PFS for all patients (A) and DR (B) for all responders (PR and CR) treated with fludarabine, cyclophosphamide, rituximab, and lumiliximab.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal